# Anebulo Pharmaceuticals (ANEB) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/ANEB
## Company Profile
- Ticker: ANEB
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
## Stock Data
- Close: 0.3 USD
- Market cap: Not available USD
- Last updated: 2026-08-11
## Business Overview
### Cannabis-Toxicity Antidote
Anebulo Pharmaceuticals develops a specific treatment for acute cannabis-induced toxicity in adults and children. The company’s approach directly blocks the cannabinoid receptor responsible for many central effects of THC.
### Selonabant
Selonabant, or ANEB-001, is a small-molecule CB1 receptor antagonist. Oral selonabant blocked or reversed key THC effects in a controlled Phase 2 proof-of-concept study in healthy adults.
### Pediatric Intravenous Strategy
Anebulo is prioritizing an intravenous formulation for pediatric cannabis poisoning rather than moving the adult oral product directly into Phase 3. The company has scaled the IV formulation and initiated a Phase 1 single-ascending-dose safety study.
## Why The Stock Is Moving

Current closing-price context is not available for ANEB.

## Future Catalysts

- Anebulo's story is now centered on selonabant and the company's decision to step away from Nasdaq. That makes the next chapter feel more like a value-maximization exercise around a finished Phase 2 asset than a broad public-development story.

## Drug Assets

- selonabant

## Recent News
- 2026-02-12 21:15 EST — [Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Updates](https://biopharmsignal.com/news/ANEB/anebulo-pharmaceuticals-reports-second-quarter-fiscal-year-2026-financial-results-and-recent-updates) — Source: Anebulo Pharmaceuticals
- 2026-02-06 14:00 EST — [Anebulo Pharmaceuticals Announces Intention to Voluntarily Delist from Nasdaq and Deregister with SEC](https://biopharmsignal.com/news/ANEB/anebulo-pharmaceuticals-announces-intention-to-voluntarily-delist-from-nasdaq-and-deregister-with-sec) — Source: Anebulo Pharmaceuticals
- 2026-01-29 14:00 EST — [Anebulo Pharmaceuticals Announces Final Results of Tender Offer](https://biopharmsignal.com/news/ANEB/anebulo-pharmaceuticals-announces-final-results-of-tender-offer) — Source: Anebulo Pharmaceuticals
- 2026-01-27 14:00 EST — [Anebulo Pharmaceuticals Announces Preliminary Results of Tender Offer](https://biopharmsignal.com/news/ANEB/anebulo-pharmaceuticals-announces-preliminary-results-of-tender-offer) — Source: Anebulo Pharmaceuticals
- 2025-12-22 14:00 EST — [Anebulo Pharmaceuticals Announces Its Intent to Commence a Self Tender Offer](https://biopharmsignal.com/news/ANEB/anebulo-pharmaceuticals-announces-its-intent-to-commence-a-self-tender-offer) — Source: Anebulo Pharmaceuticals